8-K: Colgate-Palmolive Reports Mixed Q4, Full Year 2025 Results

Colgate-Palmolive announced its fourth quarter and full year 2025 results, featuring sales growth but a significant GAAP EPS decline due to impairment charges.

Summary

• Full Year 2025 Net sales increased 1.4% to $20,382 million, with Organic sales also up 1.4%, including a 0.7% negative impact from lower private label pet volume.
• Full Year 2025 GAAP EPS declined 25% to $2.63, primarily driven by $919 million in goodwill and intangible assets impairment charges related to the skin health business.
• Full Year 2025 Base Business EPS (non-GAAP) increased 3% to $3.69.
• Net cash provided by operations reached a record $4,198 million for the full year, and $2.9 billion was returned to shareholders through dividends and share repurchases.
• Fourth Quarter 2025 Net sales increased 5.8% to $5,230 million, with Organic sales up 2.2%, including a 0.9% negative impact from lower private label pet volume.
• Fourth Quarter 2025 GAAP EPS declined 106% to $(0.05), also due to the aforementioned impairment charges.
• Fourth Quarter 2025 Base Business EPS (non-GAAP) increased 4% to $0.95.
• GAAP Gross profit margin and Base Business Gross profit margin both decreased 10 basis points to 60.2% in the fourth quarter.
• Colgate maintained global market leadership in toothpaste with a 41.3% share year to date and in manual toothbrushes with a 32.4% share year to date.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While underlying 'Base Business' performance and cash flow were solid, the significant GAAP EPS decline due to the skin health impairment charge and a cautious short-term outlook temper enthusiasm.

Positives

• Full year net sales increased 1.4% to $20,382 million.
• Full year organic sales increased 1.4%.
• Record net cash provided by operations of $4,198 million for the full year.
• Returned $2.9 billion in cash to shareholders through dividends and share repurchases.
• Fourth quarter net sales increased 5.8% to $5,230 million.
• Fourth quarter organic sales increased 2.2%.
• Base Business EPS increased 3% for the full year to $3.69 and 4% for the fourth quarter to $0.95.
• Continued global market leadership in toothpaste (41.3% share) and manual toothbrushes (32.4% share).
• Strong performance in Latin America (net sales +12.8%, organic sales +6.5%) and Africa/Eurasia (net sales +15.0%, organic sales +10.3%) in Q4.
• Expects net sales to be up 2% to 6% and organic sales growth of 1% to 4% for full year 2026.
• Expects gross profit margin expansion and double-digit GAAP EPS growth for full year 2026.

Negatives

• Full year GAAP EPS declined 25% to $2.63.
• Fourth quarter GAAP EPS declined 106% to $(0.05).
• Goodwill and intangible assets impairment charges of $919 million in Q4 2025 related to the skin health business (primarily Filorga), due to lower than expected category growth rates and weaker performance, particularly in China.
• GAAP Gross profit margin and Base Business Gross profit margin both decreased 10 basis points to 60.2% in Q4.
• North America net sales decreased 1.5% and organic sales decreased 1.8% in Q4.
• Asia Pacific net sales decreased 0.3% in Q4.
• Operating profit for Total Company (As Reported) declined 91% in Q4 to $92 million.
• Full year operating profit (GAAP) declined 23% to $3,306 million.
• Working capital as a percentage of sales worsened from (5.2)% in 2024 to (7.0)% in 2025.

Risks

• Lower than expected category growth rates and weaker than expected performance in the skin health business, particularly in China, led to impairment charges.
• Expectation of a difficult operating environment and slower category growth to continue in the short term in 2026.
• Impact of foreign exchange fluctuations on net sales (low-single-digit positive impact expected for 2026, but can be negative).
• Impact of developments in global trade relations and tariffs.
• Impact of geopolitical events and tensions, wars and military conflicts (e.g., Ukraine, the Middle East, and Venezuela).
• Limitations on the availability of up-to-date market share information, especially for certain retail channels such as eCommerce, club retailers, and discounters.
• Forward-looking statements are not guarantees of future performance and actual events or results may differ materially from those statements.

Future Outlook

For full year 2026, the Company expects net sales to increase by 2% to 6%, including a low-single-digit positive impact from foreign exchange, and organic sales growth of 1% to 4%. This organic sales growth includes an approximately 20 basis point impact from exiting the private label pet food business. On a GAAP basis, gross profit margin expansion is anticipated with advertising up on both a dollar basis and as a percentage of net sales, leading to double-digit earnings per share growth. On a non-GAAP (Base Business) basis, low to mid-single-digit earnings per share growth is expected.

Management Comments

• "We are pleased to have exited 2025 with accelerated growth momentum on both the top and bottom lines, even in the face of sluggish category growth in many markets."
• "Net sales and organic sales grew in every category during the quarter, led by strength in oral care and pet nutrition, excluding private label."
• "Our 2025 performance highlights the resilience of our business model and the strength of our brands."
• "Our new 2030 strategy builds on that success. We have laid out a clear path to accelerate our growth going forward with a focus on leveraging the global reach and penetration of our brands, building the incremental benefit of superior, science-based innovation, harnessing the power of best-in-class omni-channel demand generation, leading in capabilities like data, analytics and AI and evolving our high-impact, inclusive culture."
• "As we begin 2026, while we expect the difficult operating environment and slower category growth to continue in the short term, we are operating from a position of strength and are confident that the changes we are making will enable us to deliver consistent, compounded earnings per share growth and drive shareholder value in the long term."
• "The Company is taking the appropriate actions to improve performance and continues to believe in the growth prospects of the [skin health] business."

Industry Context

StockSavvy.ai notes that Colgate-Palmolive's performance reflects broader trends in the consumer staples sector, where established brands often demonstrate resilience in sales growth, particularly in emerging markets, despite challenging economic conditions. The strategic focus on science-based innovation and omni-channel demand generation aligns with industry efforts to adapt to evolving consumer preferences and digital retail landscapes. The impairment charge in the skin health business, particularly in China, highlights the competitive pressures and regional specific challenges faced by global consumer goods companies in diverse markets.

Comparison to Industry Standards

• Colgate's global market share of 41.3% in toothpaste and 32.4% in manual toothbrushes demonstrates a dominant position, significantly outperforming many competitors in these core categories.
• The 2026 organic sales growth guidance of 1% to 4% is generally in line with or slightly above the low-to-mid single-digit growth often seen in mature consumer staples markets, but below high-growth segments or companies with significant new product cycles.
• The record net cash provided by operations of $4,198 million indicates strong operational efficiency and cash generation, a hallmark of well-managed consumer goods companies like Procter & Gamble or Unilever, which typically prioritize consistent cash flow.
• The significant GAAP EPS decline due to impairment charges on the skin health business (Filorga) suggests a specific underperformance in that segment, contrasting with the more stable growth seen in core oral care and pet nutrition, and potentially lagging behind more agile, niche beauty and personal care brands.

Legal Proceedings

• Charges resulting from the ERISA litigation matter were excluded from non-GAAP adjustments for both Q4 and full year 2025, indicating ongoing legal matters with financial implications.

Stakeholder Impact

• Shareholders: Impacted by the GAAP EPS decline due to impairment, but also benefited from $2.9 billion returned through dividends and share repurchases. Future value creation is targeted through the new 2030 strategy and consistent EPS growth.
• Employees: Implied impact from "Strategic Growth and Productivity Program" and "2022 Global Productivity Initiative" (restructuring programs), though specific details on employee impact are not provided.
• Customers: Benefit from continued innovation and global reach of brands, particularly in oral care and pet nutrition.
• Creditors: Strong net cash provided by operations ($4,198 million) and free cash flow ($3,634 million) indicate solid ability to meet obligations.

Next Steps

• Execution of the new 2030 strategy focusing on leveraging global reach, science-based innovation, omni-channel demand generation, data/analytics/AI, and evolving culture.
• Actions to improve performance in the skin health business.
• Annual meeting of stockholders scheduled for Friday, May 8, 2026.

Key Dates

Recommendation

The filing presents a mixed picture. While the underlying "Base Business" performance shows consistent growth in sales and non-GAAP EPS, and cash generation remains strong, the significant GAAP EPS decline driven by the skin health impairment charge is a notable negative. The cautious short-term outlook for the operating environment also warrants a conservative stance. The long-term 2030 strategy is promising, but its execution and impact on the challenged skin health segment need to be monitored. For a seasoned investor, a "hold" recommendation allows for observation of the effectiveness of the new strategy and the turnaround efforts in the skin health business before committing to a stronger position.

Keywords

Colgate-Palmolive, CL, Q4 2025 Earnings, Full Year 2025 Results, SEC Filing, Consumer Staples, Oral Care, Pet Nutrition, Skin Health, Financial Results, Organic Sales, EPS, Impairment Charge, Filorga, 2026 Guidance, Dividends, Share Repurchases